 Home > Biochemistry News > Biotechnology News > Odivo combined with chemotherapy and neoadjuvant therapy can significantly improve event-free survival in non-small cell lung cancer

Odivo combined with chemotherapy and neoadjuvant therapy can significantly improve event-free survival in non-small cell lung cancer

 Last Update: 2021-12-03
 Source: Internet
 Author: User

Tags

water based shampoo

research chemical engineering

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Princeton, NJ, USA, November 9, 2021/PRNewswire/ - Bristol-Myers Squibb (NYSE: BMY) announced that the Phase III clinical study CheckMate-816 can be cut from Phase IB to Phase IIIA unless minor The primary research endpoint of improving event-free survival (EFS) in patients with cell lung cancer (NSCLC)

Dr.

The company will complete a comprehensive evaluation of the existing data in the CheckMate-816 study and announce the results of the study at an upcoming medical conference.

In the field of non-metastatic non-small cell lung cancer, Bristol-Myers Squibb and partners are jointly exploring the use of immunotherapy in neoadjuvant, adjuvant, and perioperative periods, as well as the combination with radiotherapy and chemotherapy

So far, Odivo, as a neoadjuvant or adjuvant therapy, has shown improved efficacy in four tumor types, including lung cancer, bladder cancer, esophageal cancer/gastroesophageal junction cancer and melanoma

Bristol-Myers Squibb thanks the patients and researchers who participated in the CheckMate -816 clinical trial

About CheckMate -816

CheckMate-816 is a randomized, open-label, multi-center phase III clinical study designed to evaluate the efficacy of Odivo combined chemotherapy for neoadjuvant therapy in patients with non-small cell lung cancer, regardless of PD, compared with chemotherapy alone.

About lung cancer

Lung cancer is the leading cause of cancer deaths worldwide

About Odivo

Odivo is a PD-1 immune checkpoint inhibitor that uniquely uses the body's own immune system to help the body restore its anti-tumor immune response

Based on Bristol-Myers Squibb's scientific expertise in the field of immuno-oncology (IO) treatment, Odivo has a world-leading research and development project covering various phases of clinical trials for multiple tumors, including phase III clinical trials

In July 2014, Odivo became the world's first PD-1 immune checkpoint inhibitor approved by regulatory agencies.

Source: Bristol-Myers Squibb

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.